VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4069
-0.0008 (-0.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.4077
Open0.4100
Bid0.4000 x 1200
Ask0.4199 x 1400
Day's Range0.3950 - 0.4177
52 Week Range0.3000 - 4.5800
Volume743,626
Avg. Volume1,613,263
Market Cap40.67M
Beta (3Y Monthly)11.79
PE Ratio (TTM)N/A
EPS (TTM)-3.5590
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    4 Healthcare Stocks Setting The Pace On Monday (1/14/19)

    CORAL GABLES, FL / ACCESSWIRE / January 14, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Valeritas Holdings Inc (VLRX), and Opko Health Inc (OPK) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • GlobeNewswire6 days ago

    Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that V-Go is Preferred on the OptumRx formulary. “We are very excited that V-Go is now Preferred on OptumRx formularies,” said Valeritas CEO, John Timberlake. “V-Go helps patients simplify their insulin therapy and improve their management of diabetes.

  • ACCESSWIRE17 days ago

    4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...

  • GlobeNewswire17 days ago

    Valeritas Announces V-Go® is Preferred on Humana Part D Formularies

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced that Humana, one of the nation’s leading health and well-being companies in the United States, has given V-Go Preferred status on Humana’s Part D formularies. “We are very excited that V-Go is now Preferred on Humana’s Medicare formularies, which will improve patient access to V-Go at an affordable monthly copay for its members with type 2 diabetes,” said Valeritas CEO, John Timberlake.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of VLRX earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 Valeritas Holdings Inc Earnings Call

  • 5 Beaten-Down Medical Product Stocks to Rebound in 2019
    Zackslast month

    5 Beaten-Down Medical Product Stocks to Rebound in 2019

    As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

  • GlobeNewswire2 months ago

    Valeritas CEO John Timberlake to Participate as a Panelist on “Exploring Innovation in Diabetes Tech,” at DeviceTalks West Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that John Timberlake, CEO, will be a panelist at DeviceTalks West, a MassDevice resource, being held December 11-12, 2018, at the Hilton Orange County/Costa Mesa in Costa Mesa, California. Mr. Timberlake will participate in a panel titled, “Exploring Innovation in Diabetes Tech," scheduled on Wednesday, December 12, 2018, from 11:00-11:45 AM Pacific Time. Mr. Timberlake, along with representatives from other diabetes device companies, will discuss current and future technologies for patients with diabetes.

  • GlobeNewswire2 months ago

    Study Supports Valeritas’ V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the publication of a manuscript titled “Evaluation of a Weekly Physician-Driven Bolus Titration Algorithm in Patients with Type 2 Diabetes Prescribed V-Go® Wearable Insulin Delivery Device for Basal-Bolus Therapy,” in a special Bolus Insulin issue of Annals of Diabetes, Metabolic Disorders & Control, an international, peer-reviewed journal.

  • GlobeNewswire2 months ago

    Valeritas Announces Pricing of $36 Million Public Offering

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced the pricing of its underwritten public offering of (i) 75 million shares of its common stock, (ii) series A warrants to purchase 75 million shares of its common stock and (iii) series B warrants to purchase 75 million shares of its common stock, for gross proceeds of $36 million, at a public offering price of $0.48 per share and accompanying warrants. The series A warrants have an exercise price of $0.60 per share, are immediately exercisable and will expire on the fifth anniversary of the date of issuance.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar

    Valeritas Holdings, Inc. (VLRX), a medical technology company, has signed an exclusive distribution agreement with Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, for the commercialization of its V-Go Wearable Insulin Delivery device in the GCC (Gulf Cooperation Council). V-Go® Wearable Insulin Delivery device is a simple, all-in-one, wearable insulin delivery option for adult patients with diabetes. Under the terms of the agreement, Julphar will have the rights to promote, market, and sell V-Go to diabetes clinics and patients in the GCC.

  • GlobeNewswire2 months ago

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,wearable insulin delivery option for patients with diabetes, announced today a poster titled “Relationship between Baseline BMI and Clinical Outcomes with V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes Previously Prescribed Basal-Bolus Regimens” was presented over the weekend at the 18th Annual Diabetes Technology Meeting in North Bethesda, Maryland. Obesity has been associated with higher insulin requirements in patients with type 2 diabetes, therefore evaluating the impact of body mass index (BMI), a measurement of body fat, on insulin treatment is important. This study investigated the impact to A1c and Total Daily Dose (TDD) in patients with type 2 diabetes who were switched from prior insulin regimens to V-Go when findings were stratified by established BMI strata (normal-weight, overweight, obesity class I, II or III).

  • GlobeNewswire2 months ago

    Valeritas Reports Record Revenue for the Third Quarter 2018

    - Company’s Third Consecutive Quarter with Greater than 30% Year-Over-Year Revenue Growth - BRIDGEWATER, N.J., Nov. 09, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a.

  • GlobeNewswire2 months ago

    Valeritas to Report Third Quarter 2018 Results November 9, 2018

    BRIDGEWATER, N.J., Nov. 05, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • ACCESSWIRE3 months ago

    Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analyst Report

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (VLRX), a commercial-stage medical technology company focused on people with diabetes by developing and commercializing innovative technologies. Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.